Ambrx Biopharma, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q3 2022 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ambrx Biopharma, Inc. quarterly Income Tax Expense (Benefit) history and growth rate from Q3 2022 to Q3 2023.
  • Ambrx Biopharma, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $148K.
Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $148K +$148K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.